In particular, the inhibition of tubulin deacetylation mediated by two identified tubulin deacetylases HDAC6 and SIRT2 enhances sensitivity to the anti-motility activity of paclitaxel theoretically potentiating the anti-tumor effect of the drug [65–67]. Here, SIRT2 is linked to neoplasm.